Aβ38 and Aβ43 do not differentiate between Alzheimer's disease and cerebral amyloid angiopathy
Annals of Clinical and Translational Neurology · 2024
DOI: 10.1002/acn3.51987 ↗Kurz gefasst
Fachartikel in der Zeitschrift Annals of Clinical and Translational Neurology, 2024. Verfasst von Justina Dargvainiene und 15 weiteren Autor:innen. Beteiligte Einrichtung: Institute of Clinical Chemistry, University Medical Center Schleswig-Holstein, Campus Kiel, Kiel, Germany. Hauptthemen laut MEDLINE: Alzheimer Disease, Cerebral Amyloid Angiopathy. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 16 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: Clinician Scientist Program of the Faculty of Medicine of the University of Tübingen.
Themen: Demenz
Abstract (Originalsprache)
Differential diagnosis between Alzheimer's disease (AD) and cerebral amyloid angiopathy (CAA) using cerebrospinal fluid (CSF) biomarkers is challenging. A recent study suggested that the addition of Aβ38 and Aβ43 to a standard AD biomarker panel (Aβ40, Aβ42, t‐tau, p‐tau) to improve the differential diagnosis. We tested this hypothesis in an independent German cohort of CAA and AD patients and controls using the same analytical techniques. We found excellent discrimination between AD and controls and between CAA and controls, but not between AD and CAA. Adding Aβ38 and Aβ43 to the panel did not improve the discrimination between AD and CAA.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Institute of Clinical Chemistry, University Medical Center Schleswig-Holstein, Campus Kiel, Kiel, Germany.
- Department of Neuroradiology, University Medical Center Schleswig-Holstein, Campus Lübeck, Lübeck, Germany.
- Department of Radiology and Neuroradiology, University Medical Center Schleswig-Holstein, Campus Kiel, Kiel University (CAU), Kiel, Germany.
- Department of Radiology, Diagnostical and Interventional Neuroradiology, University Hospital of Tübingen, Tübingen, Germany.
- Department of Neurology, University Medical Center Schleswig-Holstein, Campus Kiel, Kiel University (CAU), Kiel, Germany.
- Department of Neurodegeneration, Hertie Institute for Clinical Brain Research, University of Tübingen, Tübingen, Germany.
ORCID-Profile: Justina Dargvainiene, Ulf Jensen-Kondering, Benjamin Röben, Nils G Margraf, Gregor Kuhlenbäumer
Förderung
- Clinician Scientist Program of the Faculty of Medicine of the University of Tübingen
Zitieren
APA
Dargvainiene, J., Jensen-Kondering, U., Bender, B., Berg, D., Brüggemann, N., Flüh, C., Markewitz, R., Neumann, A., Röben, B., Röcken, C., Royl, G., Schulte, C., Wandinger, K. P., Weiler, C., Margraf, N. G., & Kuhlenbäumer, G. (2024). Aβ38 and Aβ43 do not differentiate between Alzheimer's disease and cerebral amyloid angiopathy. Annals of Clinical and Translational Neurology. https://doi.org/10.1002/acn3.51987
Vancouver
Dargvainiene J, Jensen-Kondering U, Bender B, Berg D, Brüggemann N, Flüh C, et al. Aβ38 and Aβ43 do not differentiate between Alzheimer's disease and cerebral amyloid angiopathy. Annals of Clinical and Translational Neurology. 2024. doi:10.1002/acn3.51987
BibTeX
@article{Dargvainiene2024,
author = {Dargvainiene, Justina and Jensen-Kondering, Ulf and Bender, Benjamin and Berg, Daniela and Brüggemann, Norbert and Flüh, Charlotte and Markewitz, Robert and Neumann, Alexander and Röben, Benjamin and Röcken, Christoph and Royl, Georg and Schulte, Claudia and Wandinger, Klaus-Peter and Weiler, Caroline and Margraf, Nils G and Kuhlenbäumer, Gregor},
title = {Aβ38 and Aβ43 do not differentiate between Alzheimer's disease and cerebral amyloid angiopathy},
journal = {Annals of Clinical and Translational Neurology},
year = {2024},
doi = {10.1002/acn3.51987}
}
EUVIMED